Repligen Corporation (RGEN)
| Market Cap | 11.68B |
| Revenue (ttm) | 366.26M |
| Net Income (ttm) | 59.93M |
| Shares Out | 52.55M |
| EPS (ttm) | 1.11 |
| PE Ratio | 192.16 |
| Forward PE | 166.67 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $213.30 |
| Previous Close | $213.57 |
| Change ($) | -0.27 |
| Change (%) | -0.13% |
| Day's Open | 214.18 |
| Day's Range | 211.95 - 214.46 |
| Day's Volume | 140,884 |
| 52-Week Range | 102.13 - 228.83 |
Financial media can often divert your attention away from the best investments.
These companies are set to keep riding upward thanks to long-term secular trends.
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Repligen (RGEN).
WALTHAM, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtua...
WALTHAM, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtua...
Repligen (RGEN) reports encouraging fourth-quarter results with sales and earnings beating estimates. The company's guidance for 2021 also beats market expectations.
Repligen (RGEN) beat estimates for both earnings and revenues in the fourth quarter of 2020.
Shares of Repligen (NASDAQ:RGEN) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share increased 160.00% year over year to $0.52, which beat the estimate of $0.31.
Repligen easily beat earnings and revenue views and guided high for the current fiscal year. RGEN stock jumped Wednesday.
WALTHAM, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fou...
WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtual...
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the latest trading session, Repligen (RGEN) closed at $223.39, marking a +1.95% move from the previous day.
Webcast and Conference Call to Be Held Wednesday, February 24, 2021 at 8:30 a.m. EST WALTHAM, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company...
On Repligen's (RGEN) fourth-quarter earnings call, investor focus will be on sales performance of its product franchisees - filtration, chromatography, protein and process analytics.
WALTHAM, Mass. and HALLE (Saale), Germany, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Protei...
Repligen (RGEN) closed the most recent trading day at $222.06, moving +1.9% from the previous trading session.
When it comes to coronavirus vaccines, think of Repligen as the man behind the curtain and RGEN stock as a tools powerhouse. Shares broke out of a cup base in January and hover in a buy zone.
The tailwinds behind the company's gains aren't going anywhere.
WALTHAM, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtual...
The bioprocessing technology company gained momentum during the coronavirus pandemic.
Based on strong fundamentals, here we talk about four healthcare stocks to keep in your watchlist for 2021.
Invest in top-ranked stocks that are likely to beat earnings estimates in the upcoming releases.
Is (RGEN) Outperforming Other Medical Stocks This Year?
WALTHAM, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the closing of its previously announced underwritten public offering of an aggregate of 1.725 millio...
WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of 1.5 million shares of its common stock at a public...
Repligen is a "pick-and-shovel" play in the bioprocessing industry. Repligen heavily invests in single-use products for use in downstream continuous manufacturing processes, which are two of the latest ...
WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that it has commenced an underwritten public offering of 1.5 million shares of its common stock. In ...
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Here we discuss three potential stocks that can gain following mass availability of vaccine. Vaccination may release pent-up demand across sectors.
Is (RGEN) Outperforming Other Medical Stocks This Year?
Repligen (RGEN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
These top-ranked stocks are likely to beat on bottom line in their next releases.
Medical stocks could be making a comeback this year. The best-performing among them include medical technology companies with high Composite Ratings, a key metric measuring growth.
The bioprocessing technology company is having a great year.
Repligen stock jumped 9% on the heels of the report to a new 52-week high of $203.90 today. And Louis Navellier sees a lot more upside for the company.
Repligen Corporation's (RGEN) CEO Tony Hunt on Q3 2020 Results - Earnings Call Transcript
Repligen (RGEN) delivered earnings and revenue surprises of 42.86% and 8.75%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
WALTHAM, Mass., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a d...
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Webcast and Conference Call to Be Held Thursday, November 5, 2020 at 8:30 a.m. EST -
Stocks Rally As Trump Set To Leave Hospital; Repligen, United Rentals, Marvell Tech Break Out
Trumps scheduled to leave the hospital and stocks recover from Friday’s sell off. Investor’s Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing d...
Here we discuss four biotech stocks, which hold solid potential even amid the coronavirus crisis that continues unabated.
WALTHAM, Mass. and HALLE (Saale), Germany, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Protei...
Repligen: A Niche Play On Biologics
Repligen hasn't seen quite the same tailwind from COVID-19 as some of its larger, more diversified rivals, but pandemic-related product development is still adding about 10% to sales.
About RGEN
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput... [Read more...]
| Industry Medical Instruments & Supplies | Founded 1981 |
| CEO Anthony Hunt | Employees 1,128 |
| Stock Exchange NASDAQ | Ticker Symbol RGEN |
Financial Performance
In 2020, Repligen's revenue was $366.26 million, an increase of 35.53% compared to the previous year's $270.25 million. Earnings were $59.93 million, an increase of 179.88%.
Analyst Forecasts
According to 9 analysts, the average rating for Repligen stock is "Strong Buy." The 12-month stock price forecast is 236.71, which is an increase of 10.98% from the latest price.